Shelley Chu

Shelley Chu is a Partner with Lightspeed Venture Partners and has two decades of venture investing and operating experience in the biopharmaceutical industry. At Lightspeed, Shelley leads the firm’s biotech investments from seed to late stage. Previously, Shelley was at Gilead, where she led R&D strategy across all therapeutic areas and business development in immuno-oncology and HBV. Shelley serves on the boards of numerous biotechnology companies and on the scientific advisory board for BioCentury.